We have examined messenger RNA (mRNA) expression of estrogen receptor (ER) ␣, wild-type ER␤ (mRNA and protein), and ER␤ exon 5 deletion variants (ER␤ ⌬5) in samples of normal human mammary gland obtained from 37 premenopausal subjects undergoing reduction mammoplasty. Comparing individual expression, ER␤ mRNA predominated, expressed in 34 of 37 samples (91%), whereas ER␣ was found in 21 of 37 cases (57%). Receptor combinations were then analyzed and compared. Most samples either coexpressed ER␣ with ER␤ (54%) or expressed just ER␤ (38%). Immunohistochemical analysis revealed that ER␤ mRNA expression mirrored that of protein. Immunoreactivity was observed in the nucleus with additional evidence of cytoplasmic staining in those epithelial cells lining the breast ducts. Sporadic immunoreactivity was also detected in stromal cells. Expression of wild type and ER␤ ⌬5 was analyzed, and their association with ER␣ was compared. Most samples coexpressed wild-type ER␤ and the splice variant (62%; P ϭ 0.05), with 30% exclusively expressing wild-type ER␤. Although samples coexpressing wild type and variant ER␤ showed no statistical association with ER␣, those samples expressing only wild-type ER␤, showed a trend toward associations with ER␣ (P ϭ 0.07). In conclusion, our data would support a role for ER␤ in the normal human mammary gland, where we propose it may be the dominant receptor. (J Clin Endocrinol Metab 85: [1601][1602][1603][1604][1605] 2000) T HE ESTROGEN receptor (ER) is a ligand-activated transcription factor that mediates the effect of estrogens in target tissues. Following the cloning of the classic ER (now known as ER␣) in 1986 (1, 2), it was believed only a single receptor existed. This was in contrast to other members of the superfamily of steroid-thyroid-retinoic acid receptors in which multiple family members are found (3). Ten years after the cloning of ER␣, steroid receptor biochemistry entered a new chapter with the cloning of a second ER, known as ER␤, initially from rodent and later from human tissues (4 -6). Both receptors show high homology at the DNA-and ligandbinding domains (96% and 58%, respectively), whereas the A/B, hinge, and F-regions are not well conserved (6). The genes for both receptors are encoded by eight exons, although these are located on different chromosomes, ER␣ on the long arm of chromosome 6 and ER␤ on chromosome 14q22-24 (7), confirming that each receptor is the product of independent genes. Differences in tissue distribution and relative expression of messenger RNA (mRNA) for both receptors have been described, with altered expression associated with carcinogenesis in both breast and ovary (8 -10). Recently, we have shown that in normal breast expression of ER␤ predominated, with exclusive expression of this receptor quite common, a feature not observed in a cohort of breast tumors (11). Furthermore, the relatively small number of cells (up to 15%) reported to express ER␣ protein in premenopausal breast tissue (12-14) raises the question that ER␤ may be significant in the normal human mammary gland.
T HE ESTROGEN receptor (ER) is a ligand-activated tran-
scription factor that mediates the effect of estrogens in target tissues. Following the cloning of the classic ER (now known as ER␣) in 1986 (1, 2), it was believed only a single receptor existed. This was in contrast to other members of the superfamily of steroid-thyroid-retinoic acid receptors in which multiple family members are found (3) . Ten years after the cloning of ER␣, steroid receptor biochemistry entered a new chapter with the cloning of a second ER, known as ER␤, initially from rodent and later from human tissues (4 -6) . Both receptors show high homology at the DNA-and ligandbinding domains (96% and 58%, respectively), whereas the A/B, hinge, and F-regions are not well conserved (6) . The genes for both receptors are encoded by eight exons, although these are located on different chromosomes, ER␣ on the long arm of chromosome 6 and ER␤ on chromosome 14q22-24 (7) , confirming that each receptor is the product of independent genes. Differences in tissue distribution and relative expression of messenger RNA (mRNA) for both receptors have been described, with altered expression associated with carcinogenesis in both breast and ovary (8 -10) . Recently, we have shown that in normal breast expression of ER␤ predominated, with exclusive expression of this receptor quite common, a feature not observed in a cohort of breast tumors (11) . Furthermore, the relatively small number of cells (up to 15%) reported to express ER␣ protein in premenopausal breast tissue (12) (13) (14) raises the question that ER␤ may be significant in the normal human mammary gland.
Additional ER mRNA isoforms, generated by alternative mRNA splicing, have been described in many tissues, including the breast. ER␣ variant mRNAs are relatively common in breast tumors (15) but are also expressed in normal breast where five different exon-deleted variants (exons 2, 3, 2-3, 5, and 7) and one truncated variant (clone 4) have been described (16) . However, the detection of ER␤ variants in the mammary gland has so far been restricted to two studies, which have provided conflicting results. Vladusic et al. (17) reported that expression of exon 5-deleted variant (ER␤ ⌬5) was confined to breast tumors and not seen in normal breast, whereas exons 5, 6, or 5-6 deletions have been identified both in breast tumors and a small number of normal human mammary tissues (18) .
The aims of this study were 3-fold. First, we analyzed and compared expression of ER␣ and ER␤ mRNA in normal mammary gland. Next, we focused on ER␤; the majority of published studies on ER␤ have presented data on gene rather than protein expression, and we sought to resolve whether gene expression paralleled that of protein using immunohistochemistry. Finally, we determined whether exon 5 deletion variants of ER␤ are expressed in normal breast and whether there were any associations with expression of ER␣.
Materials and Methods

Tissue processing
Normal human breast tissue was obtained from 37 premenopausal subjects who presented sequentially for reduction mammoplasty and who had no previous history of breast disease (mean age, 35 yr; range, 18 -42). Ethical approval was obtained, and all patients gave informed consent. Tissue was trimmed of excessive adipose tissue and snap-frozen on receipt and stored at Ϫ80 C until required. Frozen tissue was pulverized using a mortar and pestle, and total RNA was extracted with Trizol (Life Technologies, Inc., Paisley, UK) according to the manufacturer's instructions. RNA (1 g) was used as a template for first strand synthesis, as described previously (19) .
PCR amplification
Primers were obtained from Life Technologies, Inc. and were designed from published gene sequences. Primer sequences and reaction conditions for ER␣ have previously been published (19) . To detect wildtype ER␤ and ER␤ ⌬5, a nested PCR was performed as described (17) , except that 5 l complementary DNA (cDNA) was initially amplified. One microliter of resultant PCR product was removed and reamplified using a second set of primers (17) . Both PCR reactions contained: 2 U BioTaq; 10ϫ PCR buffer (containing 1.5 mm MgCl 2 ; both from Bioline, London, UK); 0.5 g of each oligonucleotide primer; 200 m each of dATP, dCTP, dGTP, and dTTP (Roche Molecular Biochemicals, East Lewes, UK); 5 l nascent cDNA (PCR 1) or 1 l PCR product from reaction 1 (PCR 2); and sterile distilled water to bring the volume to 50 l. To check cDNA integrity, fragments of glyceraldehyde-3-phosphate dehydrogenase, a standard housekeeping gene, were amplified in parallel; this was consistently positive (data not shown). As a positive control for ER␣, cDNA from the human breast cancer cell line MCF-7 was used; for ER␤, human testis cDNA was used. Negative controls included substitution of RNA or cDNA with distilled water, or substitution of cDNA with an irrelevant cDNA. These were consistently negative. All transcripts were analyzed in parallel on at least two separate occasions in a thermal cycler (Hybaid OmniGene, Teddington, UK). PCR products were analyzed by electrophoresis through a 1.2% agarose gel and visualized by ethidium bromide staining under ultraviolet illumination.
Immunohistochemistry
Cryostat sections (6 -7 ) of snap-frozen breast tissue were prepared from 10 individual cases and mounted onto polylysine-coated slides. Slides were air dried, fixed in absolute methanol for 10 min at room temperature, then rehydrated in phosphate-buffered saline. Sections were then incubated for 5 min in 3% hydrogen peroxide to block endogenous peroxide and incubated overnight at 4 C with an affinitypurified goat polyclonal antibody directed against a peptide from the N terminus of human ER␤ (N-19; Autogen Bioclear, Wiltshire, UK; 1:100 dilution). This antibody shows no cross-reactivity with ER␣. To confirm the specificity of the antibody, it was neutralized by incubation with a 5-fold excess of blocking peptide [ER␤ (N19) P; Autogen Bioclear] for 2 h at room temperature. Neutralized antibody was included as a negative control in all experiments. Positive ER␤ staining was detected using the ABC method (Vector Quick Kit; Vector Laboratories, Inc. Peterborough, UK) with diaminobenzidine as a substrate. Slides were lightly counterstained with eosin, dehydrated through graded alcohols, cleared in xylene, then mounted.
Cloning and sequencing of PCR products
PCR products were purified using Wizard DNA clean-up columns and ligated into the pGEMT Easy PCR cloning vector (both from Promega Corp., Chandlers Ford, UK). Ligated plasmids were then electroporated into competent DH5␣ Escherichia coli using a Gene Pulser (BioRad Laboratories, Inc., Hemel Hempstead, UK). DNA was prepared from transformed cells using the Wizard SV mini-prep system. Three different plasmid clones were sequenced (ALF Express; Amersham Pharmacia Biotech, Little Chalfont, UK), using DNA prepared with a 7-deaza dGTP cycle sequencing kit (Amersham Pharmacia Biotech).
Statistical analysis
Statistical analysis was performed using the Arcus software package for Windows (Research Solutions, Cambridge, UK). Fisher's exact test was used to test the difference between groups. Results were considered to be significant at P Յ 0.05.
Results
Detection of wild-type ER␤ gene and protein in normal human mammary gland
By RT-PCR, both ER␣ and ER␤ were detected. When their individual expression was considered, ER␤ predominated, expressed in 34 of 37 samples (91%). ER␣ was observed in 21 of 37 cases (57%), whereas 2 of 37 samples failed to express either receptor, perhaps indicting the presence of a third receptor. Receptor combinations were then analyzed and compared. The results are summarized in Table 1 (Fig. 1) .
Presence of ER␤ ⌬5 in normal human mammary gland
Because wild-type ER␤ gene and protein was detected in the normal human mammary gland, we next investigated whether ER␤ ⌬5 mRNA was present. A representative agarose gel showing transcripts for wild-type ER␤ (429 bp) and a smaller exon 5 deletion variant (290 bp) is shown in Fig. 2 . Sequence analysis confirmed that the smaller PCR fragment contained a 139-bp deletion (nucleotides 812-950), corresponding to the entire exon 5 of human ER␣ (similarity ϭ 99%, identity ϭ 98%, data not shown). Expression of wild type and variant ER␤ was analyzed, and their association with ER␣ was compared. As detailed in Table 2 , a significantly higher proportion of samples coexpressed wild-type ER␤ with ER␤ ⌬5 (62%; P ϭ 0.05) with fewer samples exclusively expressing wild-type ER␤. Furthermore, ER␤ ⌬5 was detected only in combination with wild-type ER␤. Samples that coexpressed wild type and variant ER␤ showed no statistical association with ER␣. However, in samples exclusively expressing wild-type ER␤, there was a suggestion of a trend toward associations with ER␣ (P ϭ 0.07). In two cases, tissue was available from both breasts. These gave identical profiles, indicating that breast tissue from the same woman expresses the same ER profile (data not shown).
Discussion
Estrogens fulfill an important role in normal breast physiology where their actions are mediated by two separate receptors, ER␣ and ER␤. Using RT-PCR analysis of total RNA Comparing individual mRNA expression for each receptor subtype, ER␤ appeared to be the dominant receptor, observed in 91% of samples, whereas ER␣ was found in 54%, with coexpression of both receptors in an equivalent number of cases. Immunohistochemical studies have confirmed the presence and distribution of ER␣ in epithelial cells from normal premenopausal mammary gland. In some studies, this is irrespective of the phase of the menstrual cycle (12, 20) , whereas others have revealed a higher proportion of ER␣-positive cells in the follicular phase (up to 15%), falling to Յ 5% in the luteal phase (21, 22) . Immunohistochemical data on ER␤ have so far been more limiting, possibly reflecting the difficulties in raising specific human antibodies against this protein. ER␤ immunoreactivity has been observed in multiple rat tissues, including cells of the ovary, testes, prostate, and paraventricular/supraoptic nuclei (23, 24) . There is scant information on its distribution in human tissues, although two recent studies have reported ER␤ immunoreactivity in bone (25) and breast (26) tissues. In the bone study, immunoreactivity was observed in nuclear extracts of human osteosarcoma cells and in sections of human bone where positivity was seen in osteoblast nuclei (25) . In the breast study, Western blot analysis showed constitutive expression of ER␤ protein in breast cancer cell lines and expression in three of five breast tumor biopsies (26) . Using frozen sections, we demonstrated ER␤ immunoreactivity in normal human breast. This was seen in the nucleus of those epithelial cells lining the breast ducts, with more limited evidence of cytoplasmic staining. Its predominant nuclear localization closely parallels the tissue distribution of ER␣, and the cytoplasmic staining concurs with the pattern of staining observed in human osteoclasts (25) . Unexpectedly, we also observed focal ER␤ immunoreactivity in stromal cells, and the presence of ER␤ in these cells has been confirmed by RT-PCR analysis of enriched stromal cell cultures (data not shown). At present, the significance of ER␤ immunoreactivity in stromal cells is unclear. Also, it is not known whether the distribution of ER␤ varies throughout the menstrual cycle, but these aspects should be the focus of future studies.
In normal breast it has been proposed that epithelial cells are hierarchical in organization, with proliferation of ER␣ Ϫ cells under the control of paracrine factors released from their ER␣ ϩ counterparts (14) . However, the demonstration of ER␤ immunoreactivity suggests that distribution/colocalization of both receptors may be relevant as those cells thought previously to be ER(␣) Ϫ may express ER␤. Our observation that a higher proportion of samples expressed ER␤ is in contrast to a recent in situ hybridization study of breast tumors, where ER␣ was expressed in 72% of samples compared with 44% of samples that expressed ER␤ (26) . This would support specific roles for each receptor in normal vs. malignant breast where levels of expression may alter in the evolution of breast cancer (8 -11) .
Because ER␤ was clearly expressed in mammary gland, we investigated whether ER␤ mRNA variants, specifically exon 5 variants, were also found. Although our results contrast those of Vladusic et al. (17) , who only detected wild-type ER␤ mRNA in normal breast tissue, this may be explained by sample size. Those investigators only analyzed a single normal breast sample using mRNA from a commercial source and two normal breast-derived organoid samples; our data show that deletion variants are not constitutively expressed. Our results, however, concur with Lu et al. (18) , who also observed wild type and variant ER␤ in normal human uterus, ovary, and mammary gland. ER␤ ⌬5 was coexpressed with wild-type ER␤ in 62% of samples, but it was not expressed alone. If translated in vivo, this exon-deleted mRNA would encode ER-like protein but which lacks exon 5, part of the ligand-binding domain (7) . Although ligand-binding affinity may be lost or altered in ER␤ ⌬5, it is known that ER␣ exon 5-deletion variants possess ligand-independent activity in yeast expression systems (28) . Because the DNA-binding domain should remain intact in ER␤ ⌬5 and would, therefore, still be expected to form ER␤ homodimers or ER␣/ER␤ heterodimers (as a result of coexpression of ER␣), this would permit interaction with estrogen response elements and subsequent transcriptional activation of target genes (29, 30) . Furthermore, it has recently been shown that ER␣/ER␤ heterodimers can be activated even if only one of the cooperating partners binds ligand (31) .
It is worth commenting that breast tissue from reduction mammoplasties may not be truly representative of normal breast tissue, and it would be of interest to analyze breast tissue from age-matched women without enlarged breasts. However, ethical considerations mean that such tissue is difficult to obtain. In some studies, tissue adjacent to breast tumors has been used as a source of normal tissue (8) , but it is questionable whether this tissue is entirely normal, given the phenotypic and genotypic changes that occur during tumor development; some of these changes must surely influence the surrounding tissue milieu. It should, however, be noted that the reduction mammoplasty sections used in this study were examined by a pathologist, who confirmed that normal tissue architecture was maintained.
Although ER␤ ⌬5 was clearly detected in over 60% of all normal samples, at present its functional significance is unknown. Studies are currently underway to compare the relative expression of ER␤ ⌬5 in premenopausal breast tumors with that of normal breast, however, no significant differences in relative expression have yet been observed in the small number of tumor samples analyzed, to date (data not shown). This is in direct contrast to ER␣ ⌬5 where higher levels are expressed in breast tumors (16) . Although more detailed studies are required, this would support the hypothesis that levels of expression of each receptor subtype may differ in normal and malignant breast (8 -11) . In conclusion, our data would endorse a role for ER␤ in the normal human mammary gland, possibly as the dominant receptor. 
